PDS Biotechnology Corporation: Business Overview, Financials & Competitive Analysis
PDS Biotechnology Corporation scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage biotech with promising Phase 2 efficacy data and FDA-backed accelerated approval pathway, but high execution risk and capital requirements. Recent VERSATILE-002 Phase 2 results showed promising median overall survival of 39.3 months and progression-free survival of 6.3 months in HPV16+ recurrent/metastatic head and neck cancer patients. However, the.
What is PDS Biotechnology Corporation's industry? PDS Biotechnology Corporation (pdsbiotech.com) operates in Biopharmaceutical/Oncology Immunotherapy. AskCyborg classifies PDS Biotechnology Corporation under Biopharmaceutical/Oncology Immunotherapy in its company registry.
PDS Biotechnology is a clinical-stage biopharmaceutical company focused on cancer treatment through its proprietary Versamune platform technology, which targets early-stage and late-stage cancers including head and ne...
Cyborg Score thesis
Early-stage biotech with promising Phase 2 efficacy data and FDA-backed accelerated approval pathway, but high execution risk and...
Read the full analyst-debate transcript →Get the Latest PDS Biotechnology Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreePDS Biotechnology Corporation Overview
Pro stress-test →PDS Biotechnology is a clinical-stage biopharmaceutical company focused on cancer treatment through its proprietary Versamune platform technology, which targets early-stage and late-stage cancers including head and neck, prostate, breast, cervical, and anal cancers. The company recently achieved positive final VERSATILE-002 Phase 2 results and secured FDA alignment for an accelerated approval pathway in January 2026.
Strategic Profile
Pro stress-test →PDS's Versamune platform activates and directs the human immune system to unleash a targeted attack against cancer cells. The platform is designed to activate immune system T-cells to target diseased cells, with key projects including PDS0101 targeting HPV-associated cancers.
Competitive Landscape
Pro stress-test →PDS Biotechnology competes in the cancer immunotherapy space with companies including Arcus Biosciences, Aura Biosciences, BriaCell Therapeutics, Ayala Pharmaceuticals, and Seagen. The company's differentiation lies in its proprietary IL-12-based Versamune platform designed to suppress tumor immunity while generating targeted T cell attacks.
Industry Context
PDS Biotechnology Corporation operates in Biopharmaceutical/Oncology Immunotherapy.
Key facts
Founded: 2005 · Headquarters: Princeton, New Jersey, US · Market cap: $32.2M